AHA GUIDELINES Bundle (free trial)

Dyslipidemia 2026

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1543908

Contents of this Issue

Navigation

Page 23 of 105

24 Management Table 7. Pharmacokinetic Properties of Statin Medications Absorption Distribution Bio-availability (%) Tmax (h) Protein Binding (%) Lipophilicity (log P ) Atorvastatin 14 1–2 ≥98 Yes, 4.1 Fluvastatin 24 <1 98 Yes, 3.2 Lovastatin <5 2–4 ≥95 Yes, 4.3 Pitavastatin 43–51 1 99 Yes, 1.5 Pravastatin 17 1–1.5 50 No, –0.2 Rosuvastatin 20 3–5 88 No, –0.3 Simvastatin <5 4 95 Yes, 4.7 Atorvastatin, lovastatin, and simvastatin are P-glycoprotein substrates and may be subject to certain drug-drug interactions. Modified with permission from Wiggins et al. Copyright © 2016 American Heart Association, Inc. CYP indicates cytochrome P450; h, hour; Tmax, time until maximum serum concentration achieved; and t1/2, drug half-life.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Dyslipidemia 2026